Cargando…

Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19

BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fangbo, Guo, Feifei, Zhang, Yi, Xu, He, Liu, Yuling, Lin, Longfei, Li, Hui, Yang, Hongjun, Huang, Luqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier GmbH. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674563/
https://www.ncbi.nlm.nih.gov/pubmed/36610129
http://dx.doi.org/10.1016/j.phymed.2022.154549
_version_ 1784833182752833536
author Zhang, Fangbo
Guo, Feifei
Zhang, Yi
Xu, He
Liu, Yuling
Lin, Longfei
Li, Hui
Yang, Hongjun
Huang, Luqi
author_facet Zhang, Fangbo
Guo, Feifei
Zhang, Yi
Xu, He
Liu, Yuling
Lin, Longfei
Li, Hui
Yang, Hongjun
Huang, Luqi
author_sort Zhang, Fangbo
collection PubMed
description BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and precise mechanism of HSBD against sepsis-induced ALI based on network pharmacology and animal experiments. MATERIALS AND METHODS: Network pharmacology was used to predict the possible mechanism of HSBD against sepsis. Next, a sepsis-induced ALI rat model via intraperitoneal lipopolysaccharide (LPS) was constructed to evaluate the level of inflammatory cytokines and the degree of lung injury. The expression of inflammation-related signaling pathways, including TLR4/NF-κB and PI3K/Akt was determined by western blot. RESULTS: Network pharmacology analysis indicated that HSBD might have a therapeutic effect on sepsis mainly by affecting inflammatory and immune responses. Animal experiments demonstrated that HSBD protected the lung tissue from LPS-induced injury, and inhibited the levels of inflammatory cytokines such as interleukin (IL)-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the serum and IL-1β, IL-5, IL-6, IL-18, GM-CSF, IFN-γ and TNF-α in the lung tissue. Western blot results revealed that HSBD downregulated the expression of TLR4/NF-κB and upregulated the expression of PI3K/Akt. CONCLUSION: The therapeutic mechanism of HSBD against sepsis-induced ALI mainly involved suppressing cytokine storms and relieving inflammatory symptoms by regulating the expression of TLR4/NF-κB and PI3K/Akt. Our study provides a scientific basis for the mechanistic investigation and clinical application of HSBD in the treatment of sepsis and COVID-19.
format Online
Article
Text
id pubmed-9674563
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier GmbH.
record_format MEDLINE/PubMed
spelling pubmed-96745632022-11-21 Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19 Zhang, Fangbo Guo, Feifei Zhang, Yi Xu, He Liu, Yuling Lin, Longfei Li, Hui Yang, Hongjun Huang, Luqi Phytomedicine Original Article BACKGROUND: Acute lung injury (ALI) is a common complication of sepsis with poor effective interventions. Huashibaidu formula (HSBD) showed good therapeutic effects in treating coronavirus disease 2019 (COVID-19) patients. PURPOSE: This study was designed to investigate the therapeutic potential and precise mechanism of HSBD against sepsis-induced ALI based on network pharmacology and animal experiments. MATERIALS AND METHODS: Network pharmacology was used to predict the possible mechanism of HSBD against sepsis. Next, a sepsis-induced ALI rat model via intraperitoneal lipopolysaccharide (LPS) was constructed to evaluate the level of inflammatory cytokines and the degree of lung injury. The expression of inflammation-related signaling pathways, including TLR4/NF-κB and PI3K/Akt was determined by western blot. RESULTS: Network pharmacology analysis indicated that HSBD might have a therapeutic effect on sepsis mainly by affecting inflammatory and immune responses. Animal experiments demonstrated that HSBD protected the lung tissue from LPS-induced injury, and inhibited the levels of inflammatory cytokines such as interleukin (IL)-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ and tumor necrosis factor (TNF)-α in the serum and IL-1β, IL-5, IL-6, IL-18, GM-CSF, IFN-γ and TNF-α in the lung tissue. Western blot results revealed that HSBD downregulated the expression of TLR4/NF-κB and upregulated the expression of PI3K/Akt. CONCLUSION: The therapeutic mechanism of HSBD against sepsis-induced ALI mainly involved suppressing cytokine storms and relieving inflammatory symptoms by regulating the expression of TLR4/NF-κB and PI3K/Akt. Our study provides a scientific basis for the mechanistic investigation and clinical application of HSBD in the treatment of sepsis and COVID-19. Published by Elsevier GmbH. 2023-01 2022-11-19 /pmc/articles/PMC9674563/ /pubmed/36610129 http://dx.doi.org/10.1016/j.phymed.2022.154549 Text en © 2022 Published by Elsevier GmbH. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Zhang, Fangbo
Guo, Feifei
Zhang, Yi
Xu, He
Liu, Yuling
Lin, Longfei
Li, Hui
Yang, Hongjun
Huang, Luqi
Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title_full Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title_fullStr Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title_full_unstemmed Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title_short Huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: Implications for treatment of COVID-19
title_sort huashibaidu formula attenuates sepsis-induced acute lung injury via suppressing cytokine storm: implications for treatment of covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674563/
https://www.ncbi.nlm.nih.gov/pubmed/36610129
http://dx.doi.org/10.1016/j.phymed.2022.154549
work_keys_str_mv AT zhangfangbo huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT guofeifei huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT zhangyi huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT xuhe huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT liuyuling huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT linlongfei huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT lihui huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT yanghongjun huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19
AT huangluqi huashibaiduformulaattenuatessepsisinducedacutelunginjuryviasuppressingcytokinestormimplicationsfortreatmentofcovid19